Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

《国家中心数据管理与共享系统操作说明书 —— 研究者部分》

Moderate elevation of serum uric acid improves short-term functional outcome in ischemic stroke patients with type 2 diabetes mellitus

First author：Yalun Dai,Yingyu Jiang

Corresponding author：Yongjun Wang

serum uric acid ischemic stroke diabetes mellitus functional outcome prognosis

essential_information

2023-07-19

Published articles

Journal：BMC Geriatrics

Publication type: Original Articles

IF(IF): 4.1

PMID: 37468868 Link To Pubmed Full text Download

Background And Purpose

Serum uric acid (SUA), as the end product of purine catabolism diffused in the blood, is positively associated with the risk of type 2 diabetes mellitus (T2DM). However, the association of the fluctuation of SUA and stroke functional outcomes in ischemic stroke (IS) patients with T2DM is still unclear. This study aimed to evaluate the association between the fluctuation of SUA and short-term functional outcome in IS patients with T2DM.

Method

All T2DM patients diagnosed with IS in the China National Stroke Registry III were included. ∆SUA, which was defined as the difference between the SUA levels at baseline and 3 months at discharge, was classified into two groups, i.e., elevated ∆SUA (∆SUA>0) and reduced ∆SUA (∆SUA≤0). The primary outcome was poor functional outcomes (Modified Rankin Scale, 3–6) at 3 months after IS.

Conclusion

This study showed that elevated ∆SUA in the range of 0–100 μmol/L at 3 months after IS was relevant to a reduced risk of poor functional outcomes in T2DM population, whereas the association of elevated ∆SUA beyond such a range with functional outcomes was not statistically significant.

Main results

Among the 1255 participants (mean age: 61.6±9.8 years), 64.9% were men. Patients with elevated ∆SUA had a lower incidence of poor functional outcomes at 3 months. Compared with reduced ∆SUA, elevated ∆SUA at 0–50 μmol/L (odds ratio [OR]=0.46, 95% confidence interval [CI]=0.28–0.78, p=0.004) and 50–100 μmol/L (OR=0.40, 95% CI=0.21–0.77, p=0.006) was significantly correlated with a reduced risk of poor functional outcomes at 3 months.